Helus Pharma to Host Investor Presentation on October 21, 2026
Key Highlights
- ➤Investor presentation scheduled for October 21, 2026, at 9:00 a.m. EDT
- ➤HLP003 remains in Phase 3 development for adjunctive major depressive disorder treatment
- ➤HLP004 remains in Phase 2 development for generalized anxiety disorder
- ➤Presentation will feature key opinion leaders and executive leadership Q&A
NEW YORK and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce that the Company will host an investor presentation on October 21, 2026.
Discussion topics will include HLP003, the Company’s proprietary NSA in Phase 3 development for the adjunctive treatment of major depressive disorder (“MDD”), and HLP004, its proprietary NSA in Phase 2 development for generalized anxiety disorder (“GAD”). The presentation will also include key opinion leaders’ perspectives on the current and evolving depression and anxiety treatment landscape, and a question-and-answer session with members of Helus Pharma’s executive leadership team.
Get started
Create a free account to read the full story.